KLOW
Research Use Only
Buy KLOW 80mg in Australia from Aussie Peptide Hub — a four-component research blend containing GHK-Cu, BPC-157, TB-500 and KPV, supplied as a lyophilised powder for in vitro laboratory research and scientific investigation only. KLOW is available for purchase in Australia with fast domestic shipping.
KLOW combines four distinct research peptides into a single formulation. Its individual components have been investigated across experimental models involving extracellular matrix biology, cellular migration, inflammatory signalling and tissue-repair processes. Research on the complete KLOW combination itself remains limited.
This compound is intended strictly for use in controlled research environments and is not approved for human or veterinary use.
Why Researchers Choose Aussie Peptide Hub for KLOW in Australia
• ≥99.0% purity verified by Certificate of Analysis (COA)
• RP-HPLC quality verification
• GMP-compliant, ISO 9001:2008 certified facility
• Fast Australian dispatch — most orders ship within 24–48 hours
Technical Specifications
• Product: KLOW Peptide Blend
• Total Content: 80mg
• GHK-Cu: 50mg
• BPC-157: 10mg
• TB-500: 10mg
• KPV: 10mg
• Classification: Four-component research peptide blend
• Appearance: Lyophilised powder
• Storage: Store dry at 2–8°C
Research Context
KLOW combines four chemically distinct research peptides, each with its own area of experimental investigation:
• GHK-Cu — a naturally occurring copper-binding tripeptide investigated in relation to extracellular matrix remodelling, collagen biology and cellular repair processes.
• BPC-157 — a synthetic pentadecapeptide investigated primarily in preclinical models involving tissue repair, angiogenic signalling and gastrointestinal tissues.
• TB-500 — a synthetic peptide associated with thymosin beta-4 research, including studies of actin regulation, cell migration and tissue-remodelling processes.
• KPV — the Lys-Pro-Val tripeptide derived from the C-terminal region of α-MSH and investigated experimentally for its effects on inflammatory signalling pathways.
The KLOW formulation brings these four peptides together in a 50:10:10:10 mg ratio, for a total of 80mg per vial. Importantly, evidence relating to the individual components should not be interpreted as evidence that the combined KLOW formulation produces the same effects.
Product Disclaimer
• This product is intended solely for scientific research and education
• Not for use in humans or animals
• Not a drug, food, cosmetic, or dietary supplement
• No therapeutic or medical claims are made for this product
Manufactured in a GMP-compliant, ISO 9001:2008 facility. Each batch is analysed to verify identity, quality and purity.